Etrumadenant (AB928) is a potent, dual antagonist of the A2aR and A2bR adenosine receptors with Kb of 1.5 and 2.0 nM, respectively.
AB928 displays high selectivity towards related receptors (A1R, A3R, CD73, CD39, NTPDase 2/3).
AB928 is a potent inhibitor of NECA-mediated A2aR activation on cell lines, potently reverses adenosine-mediated CD8+ T cell suppression, potently inhibits cAMP-mediated pCREB activation in human leukocyte populations in whole blood.
AB928 inhibits tumor micro-environment adenosine generation and signaling for the treatment of cancer.
